Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (141-150 of 703) with videos related to

Pageof 71
Sort By:
Methods in Enzymology|January 1, 1982
Ribulosebisphosphate carboxylase/oxygenase from Rhodospirillum rubrumJ V Schloss, E F Phares, M V Long, et al.
The Australasian Journal of Dermatology|December 10, 2013
Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinibRachael Anforth, Michael Liu, Bao Nguyen, et al.
European Journal of Endocrinology|December 1, 2017
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanomaEmma S Scott, Georgina V Long, Alexander Guminski, et al.
Journal of Bacteriology|January 1, 1979
Isolation, characterization, and crystallization of ribulosebisphosphate carboxylase from autotrophically grown Rhodospirillum rubrumJ V Schloss, E F Phares, M V Long, et al.
Frontiers in Immunology|December 5, 2022
The effect of organ-specific tumor microenvironments on response patterns to immunotherapyJordan W Conway, Jorja Braden, James S Wilmott, et al.
Oncoimmunology|March 11, 2026
Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanomaJesse R Brown, Bernadette Pedersen, Georgina V Long, et al.
Pathology|November 18, 2022
Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanomaElizabeth Paver, Karina Aivazian, Fiona Maclean, et al.
The Annals of Thoracic Surgery|December 1, 1995
Time-related hemodynamic changes after aortic replacement with the freestyle stentless xenograftS Westaby, N Amarasena, V Long, et al.
ESMO Open|June 21, 2025
Do BRAF-targeted therapies have a role in the era of immunotherapy?J Braden, J W Conway, J S Wilmott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid TumorsKyriakos P Papadopoulos, Karen Autio, Talia Golan, et al.
Pageof 71

Showing results (141-150 of 703) with videos related to

Sort By:
Pageof 71
Methods in Enzymology|January 1, 1982
Ribulosebisphosphate carboxylase/oxygenase from Rhodospirillum rubrumJ V Schloss, E F Phares, M V Long, et al.
The Australasian Journal of Dermatology|December 10, 2013
Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinibRachael Anforth, Michael Liu, Bao Nguyen, et al.
European Journal of Endocrinology|December 1, 2017
The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanomaEmma S Scott, Georgina V Long, Alexander Guminski, et al.
Journal of Bacteriology|January 1, 1979
Isolation, characterization, and crystallization of ribulosebisphosphate carboxylase from autotrophically grown Rhodospirillum rubrumJ V Schloss, E F Phares, M V Long, et al.
Frontiers in Immunology|December 5, 2022
The effect of organ-specific tumor microenvironments on response patterns to immunotherapyJordan W Conway, Jorja Braden, James S Wilmott, et al.
Oncoimmunology|March 11, 2026
Prednisolone modulates CD8⁺ and regulatory T-cell activity to dampen response to immune checkpoint inhibitor therapy in melanomaJesse R Brown, Bernadette Pedersen, Georgina V Long, et al.
Pathology|November 18, 2022
Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanomaElizabeth Paver, Karina Aivazian, Fiona Maclean, et al.
The Annals of Thoracic Surgery|December 1, 1995
Time-related hemodynamic changes after aortic replacement with the freestyle stentless xenograftS Westaby, N Amarasena, V Long, et al.
ESMO Open|June 21, 2025
Do BRAF-targeted therapies have a role in the era of immunotherapy?J Braden, J W Conway, J S Wilmott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid TumorsKyriakos P Papadopoulos, Karen Autio, Talia Golan, et al.
Pageof 71